PCR data
| Patient . | Idarubicin during induction . | PML-RARα isoform . | PCR at CR* . | Follow-up PCRs* . |
|---|---|---|---|---|
| 1 | No | Long | Positive | Negative at 3, 7, 11, and 13 months† (after 3, 6, 8, and 8 post-CR courses) |
| 2 | No | Long | Negative | Negative at 3, 6, 9, and 12 months† (after 2, 5, 8, and 8 post-CR courses) |
| 3 | No | Short | Positive | Negative at 2, 4, 7, 10, and 12 months† (after 2, 4, 6, 8, and 8 post-CR courses) |
| 6 | No | Short | Not done | Negative at 2 and 4 months† (after 1 and 3 post-CR courses) |
| 7 | No | Long | Positive | Negative at 4 months†(after 3 post-CR courses) |
| 8 | Yes | Short | Negative | Negative at 2 months, positive at 5 months, negative at 9 and 11 months†,‡ (after 2, 4, 8, and 8 post-CR courses) |
| 9 | No | Long | Negative | Negative at 3, positive at 5 months, negative at 8 months†,2-153 (after 2, 4, and 6 post-CR courses) |
| 10 | No | Short | Not done | Negative at 2, 4, and 6 months† (after 2, 4, and 6 post-CR courses) |
| 11 | Yes | Variable | Not done | Negative at 1 month† (after 1 post-CR course) |
| 13 | No | Short | Inadequate | Negative at 2 and 5 months† (after 2 post-CR courses) |
| 14 | No | Unknown2-155 | Negative | Negative at 2 and 4 months† (after 2 and 4 post-CR courses) |
| 15 | No | Long | Not done | Negative at 2 months†(after 2 post-CR courses) |
| Patient . | Idarubicin during induction . | PML-RARα isoform . | PCR at CR* . | Follow-up PCRs* . |
|---|---|---|---|---|
| 1 | No | Long | Positive | Negative at 3, 7, 11, and 13 months† (after 3, 6, 8, and 8 post-CR courses) |
| 2 | No | Long | Negative | Negative at 3, 6, 9, and 12 months† (after 2, 5, 8, and 8 post-CR courses) |
| 3 | No | Short | Positive | Negative at 2, 4, 7, 10, and 12 months† (after 2, 4, 6, 8, and 8 post-CR courses) |
| 6 | No | Short | Not done | Negative at 2 and 4 months† (after 1 and 3 post-CR courses) |
| 7 | No | Long | Positive | Negative at 4 months†(after 3 post-CR courses) |
| 8 | Yes | Short | Negative | Negative at 2 months, positive at 5 months, negative at 9 and 11 months†,‡ (after 2, 4, 8, and 8 post-CR courses) |
| 9 | No | Long | Negative | Negative at 3, positive at 5 months, negative at 8 months†,2-153 (after 2, 4, and 6 post-CR courses) |
| 10 | No | Short | Not done | Negative at 2, 4, and 6 months† (after 2, 4, and 6 post-CR courses) |
| 11 | Yes | Variable | Not done | Negative at 1 month† (after 1 post-CR course) |
| 13 | No | Short | Inadequate | Negative at 2 and 5 months† (after 2 post-CR courses) |
| 14 | No | Unknown2-155 | Negative | Negative at 2 and 4 months† (after 2 and 4 post-CR courses) |
| 15 | No | Long | Not done | Negative at 2 months†(after 2 post-CR courses) |
At 10−4; in addition patients 16 and 18 were negative at complete remission (CR) and patients 17 and 19 were positive; none of these patients received idarubicin and none have yet had follow-up polymerase chain reaction (PCR) tests.
From CR date.
PCR showed the long isoform although at presentation only the short form was detected, suggesting that 5-month result was a false positive; the PCRs at 9 and 11 months were negative, adding credence to this suggestion.
PCR showed the short isoform although at presentation only the long form was detected, suggesting that 5-month result was a false positive; the PCR at 8 months was negative, supporting this suggestion.
But t(15;17) present at diagnosis.